The spinout of Yamaguchi University and National Cancer Centre Japan has raised the cash from investors including Dai-ichi Life and Binex.

Noile-Immune Biotech, a Japan-based developer of chimeric antigen receptor T-cell therapy for solid tumours spun out of Yamaguchi University and National Cancer Centre Japan, has raised ¥2.38bn ($21.9m) in series C funding.
The round was backed by insurer Dai-ichi Life, pharmaceutical firm Binex, biotech firm Bigen and packaging plant operator Shibuya Kogyo, as well as Binex Holdings, Healthcare Innovation Investment and KD Bio Investment Fund.
Founded in 2015, Noile-Immune is working on cancer immunotherapies. Its lead programme, NIB-101,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in